Superworth

Adaptive Biotechnologies price to sales ratio ADPT

Market value divided by revenue over the last twelve months, since 2020.

Today, Nov 2, 2026
13.0×
7-year median
8.5×
Against its 7-year history
67th
percentile: 0 is its lowest day, 100 its highest
7-year range
2.0× to 100×
Peer median
7.0×

Adaptive Biotechnologies' price to sales ratio is 13.0× as of Nov 2, 2026.

That is above its 7-year median of 8.5×, higher than on 67% of days in the last 7 years.

Over that time it ranged from 2.0× in Apr 2024 to 100× in Jan 2021.

The median for 10 biotech stocks of a similar size is 7.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far13.0×6.9×15.2×
202510.1×5.4×12.9×
20245.2×2.0×5.3×
20233.9×2.8×8.5×
20226.5×5.6×22.3×
202127.0×24.4×100×
202087.5×29.3×92.6×

Against its peers

Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first, today.

CompanyPrice to sales ratio
ADPTAdaptive Biotechnologies13.0×
ADMAAdma Biologics4.8×
VCELVericel6.8×
KRYSKrystal Biotech19.9×
RGENRepligen12.4×
TECHBIO-TECHNE9.4×
HALOHalozyme Therapeutics8.8×
NBIXNeurocrine Biosciences4.4×
EXELExelixis7.1×
MGTXMeiraGTx2.3×
ALNYAlnylam Pharmaceuticals4.4×
Peer median7.0×

Where Adaptive Biotechnologies ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Adaptive Biotechnologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.